Erratum: lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma (Oncology Letters (2021) 21 (455) DOI: 10.3892/ol.2021.12716)

HIDEHARU YAMADA, MASANOBU TAKAHASHI, MUNENORI WATANUKI, MIKA WATANABE, SAKURA HIRAIDE, KEN SAIJO, KEIGO KOMINE, CHIKASHI ISHIOKA

Research output: Contribution to journalComment/debatepeer-review

Abstract

Subsequently to the publication of the above paper, the authors realized that the layouts of Tables I and III had been presented incorrectly, and that they had overlooking acknowledging researchers who had provided them with the cell lines in the Acknowledgements section of the paper. Consequently, the correctly organized versions of Tables I and 3 are shown on the subsequent pages. Concerning the oversight with the Acknowledgements section, this section of the declarations should be changed to the following (added text is highlighted in bold):. (Table Presented).

Original languageEnglish
Article number698
JournalOncology Letters
Volume22
Issue number4
DOIs
Publication statusPublished - 2021 Oct

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Erratum: lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma (Oncology Letters (2021) 21 (455) DOI: 10.3892/ol.2021.12716)'. Together they form a unique fingerprint.

Cite this